HRP20070122A2 - Medicinal solution for disorder of the alimentary tract - Google Patents
Medicinal solution for disorder of the alimentary tractInfo
- Publication number
- HRP20070122A2 HRP20070122A2 HR20070122A HRP20070122A HRP20070122A2 HR P20070122 A2 HRP20070122 A2 HR P20070122A2 HR 20070122 A HR20070122 A HR 20070122A HR P20070122 A HRP20070122 A HR P20070122A HR P20070122 A2 HRP20070122 A2 HR P20070122A2
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- digestive tract
- solution
- tissues
- disease
- Prior art date
Links
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 241000590002 Helicobacter pylori Species 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- QSMZBYIJYZLHER-UHFFFAOYSA-M [O-]Cl=O.OCl=O.OCl=O.O.[Na+] Chemical compound [O-]Cl=O.OCl=O.OCl=O.O.[Na+] QSMZBYIJYZLHER-UHFFFAOYSA-M 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 210000001198 duodenum Anatomy 0.000 abstract 1
- 208000010227 enterocolitis Diseases 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 229940037467 helicobacter pylori Drugs 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
- 239000003440 toxic substance Substances 0.000 abstract 1
Abstract
Otopina za liječenje bolesti digestivnog trakta se koristi za liječenje ulkusne bolesti želuca i duodenuma izazvanih bakterijom Helikobakter pylori, liječenje enterokolita razne etiologije, liječenjeCrohnove bolesti i ulceroznog kolitisa i koristi se u liječenju bolesnika sa AIDS-om kod kojih postoje izražene promjene na digestivnom traktu kao posljedica smanjenog imuniteta bolesnika. Djelatna komponenta u Otopini za liječenje bolesti digestivnog trakta je atomski kisik koji se oslobađa kao posljedica labilne veze u molekuli natrij oksigen klorita. Vrlo efikasno uništava sve vrste mikroorganizama, a pritom ne djeluje štetno na površine na kojima se primjenjuje. Razlaže nekrotična i raspadnuta tkiva pretvarajući ih u netoksična jedinjenja,oksigenira tkiva i pomaže epitalizaciji oštećenihpovršina. Ne resorbira se i ne dospijeva u sistemsku cirkulaciju. Ne posjeduje toksične tvari i raspada se na netoksična jedinjenja.The solution for the treatment of diseases of the digestive tract is used for the treatment of gastric ulcer and duodenum caused by Helicobacter pylori, the treatment of enterocolitis of various etiologies, the treatment of Crohn's disease and ulcerative colitis, and is used in the treatment of AIDS patients with severe changes in the digestive tract as a consequence decreased patient immunity. The active ingredient in the Digestive Tract Disease Solution is the atomic oxygen released as a result of the labile bond in the sodium oxygen chlorite molecule. It destroys all kinds of microorganisms very effectively, without affecting the surfaces on which it is applied. It breaks down necrotic and decayed tissues by converting them into non-toxic compounds, oxygenates the tissues and helps epithelize the damaged surfaces. It is not resorbed and does not enter the systemic circulation. It is free of toxic substances and decomposes into non-toxic compounds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20070122A HRP20070122A2 (en) | 2007-03-26 | 2007-03-26 | Medicinal solution for disorder of the alimentary tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20070122A HRP20070122A2 (en) | 2007-03-26 | 2007-03-26 | Medicinal solution for disorder of the alimentary tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20070122A2 true HRP20070122A2 (en) | 2008-10-31 |
Family
ID=39876487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20070122A HRP20070122A2 (en) | 2007-03-26 | 2007-03-26 | Medicinal solution for disorder of the alimentary tract |
Country Status (1)
| Country | Link |
|---|---|
| HR (1) | HRP20070122A2 (en) |
-
2007
- 2007-03-26 HR HR20070122A patent/HRP20070122A2/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2509892T3 (en) | Administration of an agent for bowel cleansing and antibiotic for the treatment of intestinal disease | |
| Meganathan et al. | Evaluation of hepatoprotective effect of omega 3-fatty acid against paracetamol induced liver injury in albino rats | |
| Wallace et al. | Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics | |
| EP2364144A4 (en) | Dosage form for insertion into the mouth | |
| NZ607189A (en) | Materials and methods for improving gastrointestinal function | |
| NO20050896L (en) | Probiotics for neuromuscular functions of the intestine | |
| WO2008085484A3 (en) | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid | |
| MX2009003372A (en) | Non-mucoadhesive film dosage forms. | |
| PE20061094A1 (en) | ORAL LIQUID FORMULATION INCLUDING LIVE ATTENUATED ROTAVIRUS ANTIGEN | |
| AR075423A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING AN SGLT-2 INHIBITOR, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, TREATMENT METHODS AND ITS USES | |
| BR112015010867A2 (en) | ventilated bite block for use in endoscopy procedures | |
| NO20065915L (en) | Improving barrier integrity in HIV patients | |
| AR062659A1 (en) | COMPOSITION OF LEVODOPA SUSTAINED RELEASE AND METHOD FOR USE | |
| AR035652A1 (en) | A NUTRITIONAL COMPOSITION, USEFUL TO COMBAT INFECTION IN THE GASTROINTESTINAL TRACT CAUSED BY HELICOBACTER TYPE ORGANISMS, THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF MEDICINES, OR FOOD PRODUCTS AND THE PROCEDURE TO PREPARE SUCH COMPOSITION | |
| RU2008107596A (en) | COMPOSITIONS OF PARTICLES, INCLUDING ALGINATE AND / OR ALGINIC ACID | |
| ES2149733T1 (en) | ORAL PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE CONTAINING 5-ASA AND METHOD FOR THE TREATMENT OF INTESTINAL DISEASES. | |
| CO5560554A2 (en) | PHARMACEUTICAL COMPOSITION INCLUDING LUMIRACOXIB | |
| Jung et al. | Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis | |
| CO5580741A2 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A 5HT1 RECEIVER AGONIST | |
| MD3904F1 (en) | Composition for biosoluble medicated film for treatment of parodentium affections and of lesions of tunica mucosa of mouth (variants) | |
| MD3905G2 (en) | Remedy of durable action in the form of gel for treatment of parodentium affections (variants) | |
| ATE457721T1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING PHARMACEUTICAL ACTIVE INGREDIENTS ABSORBED ON TITANIUM DIOXIDE DNANOPARTICLES | |
| HRP20070122A2 (en) | Medicinal solution for disorder of the alimentary tract | |
| BRPI0410374A (en) | pharmaceutical composition comprising valsartan | |
| DE60322228D1 (en) | FAST CRUMPING TABLET |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090428 Year of fee payment: 4 |
|
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| OBST | Application withdrawn |